Protalix BioTherapeutics, Inc. (PLX) Stock: Is This Biotech Stock Worth Your Attention?

0

Protalix BioTherapeutics, Inc. (PLX) is working its way for to the top in the market in today’s trading session. The company, one that is focused on the biotech sector, is currently trading at $0.49 after climbing 14.16% so far in today’s session. In terms of biotechnology stocks, there are several aspects that have the potential to cause price movement in the market. News tends to be one of the biggest reasons for the movement. Here are the most recent stories relating to PLX:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Mar-13-19 05:15PM Protalix BioTherapeutics to Postpone the 2018 Financial Results and Corporate Update Conference Call
Mar-12-19 10:47AM When Will Protalix BioTherapeutics, Inc. (NYSEMKT:PLX) Turn A Profit?
Mar-06-19 07:30AM Protalix BioTherapeutics to Hold Full-Year 2018 Financial Results and Corporate Update Conference Call on March 14, 2019
Feb-07-19 08:08AM The Daily Biotech Pulse: Galapagos-Evotec Forge Fibrosis Partnership, Sanofi Earnings, Alector To Debut
Feb-05-19 07:00AM Protalix BioTherapeutics Presents Preliminary Data from the BRIGHT Study of pegunigalsidase alfa for the Treatment of Fabry Disease at the 15th Annual WORLDSymposium 2019

However, any time investors are making a decision with regard to investing, investors should look into much more than just news, this is especially the case in the highly speculative biotechnology space. Here’s what’s happening in regard to Protalix BioTherapeutics, Inc..

Recent Movement From PLX

While a single session gain, like the move that we’re seeing from Protalix BioTherapeutics, Inc. might cause excitement in some investors, that alone shouldn’t be the basis of a decision to, or not to, buy a company’s stock. It is always important to look into trends just a single trading day. When it comes to PLX, below are the returns that investors have experienced:

  • Past 7 Days – Over the last five trading sessions, PLX has seen a price change amounting to 7.89%.
  • Past Month – The monthly returns from Protalix BioTherapeutics, Inc. has been 9.72%.
  • Past Three Months – In the past quarter, the stock has generated a ROI that comes to 18.86%
  • Past Six Months – Throughout the previous six months, investors have seen a change that works out to -0.49% from the stock.
  • Year To Date – Since the the first trading session of this year PLX has resulted in a return on investment of 57.88%.
  • Annually – Finally, in the past full year, we’ve seen performance that works out to -15.34% out of PLX. Over this period of time, the stock has traded at a high of -40.84% and a low price of 81.85%.

Ratios To Watch

Digging into various key ratios associated with a company generally gives investors a look of just how risky and/or potentially profitable a pick might be. Below are a few of the key ratios to consider when looking at PLX.

Short Ratio – The short ratio is a measure of short interest. As the ratio goes higher, it means that more investors are expecting that the value of the stock is going to fall. Throughout the sector, biotech stocks can come with a higher short ratio. On the other hand, we tend to see a lot of short squeezes in the industry. Nonetheless, when it comes to Protalix BioTherapeutics, Inc., it’s short ratio is 4.41.

Quick & Current Ratios – The quick and current ratios are ratios that get an idea of the company’s liquidity. Basically, they measure the company’s abilities to cover its debts as they mature based on quick assets or current assets. Because many biotech several companies are reliant on continued investor support, these ratios can be bad. However, quite a few gems in the biotechnology space come with positive quick and current ratios. In terms of PLX, the quick and current ratios come to 0 and 0 respectively.  

Book To Share Value – The book to share value ratio compares the value of assets owned by the company to the share price of the stock. In this particular case, the book to share value ratio equates to -0.44.

Cash To Share Value – Finally, the cash to share value ratio compares the total cash on hand to the value of shares. Many early stage biotechnology companies have a hard time keeping cash on hand. So, when investing in the biotechnology industry, this is a very important ratio to consider. In the case of PLX, the cash to share value ratio comes to 0.

How Analysts Feel About Protalix BioTherapeutics, Inc.

While it’s never a good idea to unknowingly follow the opinions of analysts, it is a smart idea to consider their thoughts in order to validate your own thoughts when it comes to making investment decisions in the biotech industry. Below are|Here are} the recent moves that we have seen from analysts with regard to PLX.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Apr-17-17 Reiterated Rodman & Renshaw Buy $4 → $5
Apr-04-16 Initiated Rodman & Renshaw Buy $3.50
Apr-23-15 Upgrade Jefferies Hold → Buy $2 → $2.60
Nov-12-14 Reiterated R. F. Lafferty Buy $8 → $5
Jan-24-14 Initiated R. F. Lafferty Buy $8

Moves From Big Money Players

An interesting fact that I have learned so far in my short period on Earth is that smart investors tend to follow big money investors. That is to say, investors that are looking to keep the risk down will watch investments made by institutional investors and insiders. So, what does the big money picture look like as it relates to PLX? Here’s the data:

Institutions own 9.74% of the company. Institutional interest has moved by 0 over the past three months. When it comes to insiders, those who are close to the company currently own 6.23% percent of PLX shares. Institutions have seen ownership changes of an accumulative 0.00% over the last three months.

What’s Going On With Share Counts?

Investors tend to be interested in the amounts of shares both outstanding and available. In terms of Protalix BioTherapeutics, Inc., currently there are 148.38M with a float of 125.96M. These numbers mean that out of the total of 148.38M shares of PLX that are out there today, 125.96M are able to trade hands by the public.

I also find it important to take a look at the short percent. Think about it, if a high percentage of the float available for trading is sold short, the overall opinion among investors is that the company is going to lose value. As far as PLX, the percentage of the float that is shorted is 2.25%. In general, concerning short percent of the float is anything over 40%. Nonetheless, I have seen that a short ratio over 26% is generally a a play that could prove to be very risky.

Financial Performance

What have ween seen from PLX in terms of financial results?Here’s the information:

  • Analyst Expectations – As it stands, Wall Street analysts have expectations that PLX will create EPS coming to a total of -0.06, with -0.05 to be reported in the earnings report for the current quarter. Although this information isn’t tide to earnings, because we are chatting about Wall Street analysts, the stock is presently rated a 0 on a scale from 1 to 5 on which 1 is the worst possible Wall St. analyst grade and 5 is the best.
  • 5-Year Sales – In the past half decade, Protalix BioTherapeutics, Inc. has reported a movement in sales volume that works out to be 0. Earnings per diluted share in the last half decade have experienced a change of 0.
  • Q/Q – when it comes to quarter over quarter data, or Q/Q data as it is often explained in today’s society, PLX has experienced a change in earnings that comes to a total of 0. Protalix BioTherapeutics, Inc. has also experienced movement in regard to sales that totals -91.20%.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Will You Help Me Become A Better AI?

As a computer, I’m heavily dependent on humans. You may not consider this when reading my articles, but it was a human! While, my creator made it possible for me to learn, it is much simpler to do so through the receipt of feedback from humans. Below this article, you will find a comment section. If you would like for me consider other information, update the way in which I write something, look at data from an alternative angle, or if you’d like to tell me anything else, I want to hear from you. To let me in on your thoughts take a moment to leave a comment below. I will read your lesson and I will use it to become a better artificial intelligence to serve you!

LEAVE A REPLY

Please enter your comment!
Please enter your name here